Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2013-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The general aim of the study is to determinate safety, tolerability and early pharmacokinetics of cardiotrophin.1 in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study With Darapladib to Collect Tolerability Information

NCT00704431

Atherosclerosis

COMPLETED PHASE1

Study to Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Idarucizumab in Chinese Healthy Male and Female Volunteers Who Had Taken Dabigatran Etexilate and Whose Plasma Concentrations of Dabigatran Were at or Close to Steady State

NCT03086356

Healthy Volunteers

COMPLETED PHASE1

A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

NCT01294709

Angina Pectoris Coronary Heart Disease Calcitonin Gene-related Peptide Receptor

COMPLETED PHASE1

Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate

NCT01688830

Healthy

COMPLETED PHASE1

Study of LC23-1306 in Healthy Male Subjects

NCT01526577

Acute Coronary Syndrome

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardiotrophin-1

Group Type EXPERIMENTAL

recombinant human cardiotrophin-1

Intervention Type DRUG

Single dose intravenous administration

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Single dose intravenous administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

recombinant human cardiotrophin-1

Single dose intravenous administration

Intervention Type DRUG

Placebo

Single dose intravenous administration

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female, between the ages of 18 and 55.
* Healthy condition (no suffering from known acute or chronic disease)
* No clinically important abnormal physical or laboratory findings at the screening examination.
* Normal or clinically acceptable ECG.
* Normal blood pressure (systolic: 90-140 mmHg; diastolic: 50-90 mmHg) and heart rate (40-100 bpm).
* Body Mass Index of 19.0-29.0 (kg/m2).
* Ability to communicate well with the investigator and to comply with the requirements of the entire study.
* Willingness to give written informed consent (prior to any study-related procedures being performed) and to be able to adhere to the study restrictions and examination schedule.
* For female subjects with childbearing potential: use of a known highly effective method of birth control, defined as those which results in a low failure rate: i.e. less 1% per year, (contraceptive pills, intrauterine contraceptive device, implants, vasectomized partner or sexual abstinence), for at least three consecutive months prior to the study, during the study and one month after the end of the study.
* For male subjects with partners of child bearing potential: use of appropriate contraceptive methods (vasectomy, condoms or sexual abstinence), for at least the study period and one month after the end of the study.

Exclusion Criteria

* Administration of any investigational drug in the period within three months prior to informed consent.
* Use of any prescription medication during the period 0 to 30 days or over-the-counter medication during the 0 to 5 days before entry to the study.
* Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study.
* Serious adverse reaction or hypersensitivity to any drug.
* Inability to communicate or co-operate with the investigator because of a language problem, poor mental development or impaired cerebral function.
* History of drug dependence (except tobacco) or psychiatric illness within the past 2 years.
* Consumption of alcohol within 24 hours prior to dose administration.
* Presence of pain incurred by unknown causes.
* Pregnancy or nursing.
* Positive urine drug screen for drugs with a high potential for abuse and low persistence in the urine.
* Inability to refrain from smoking during study days.
* Any other condition which, in the opinion of the investigators, is likely to interfere with the successful collection of the measures required for the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes